drugset
drugset / Trial / NCT05309304

Cefazolin PK Study 3g vs 2g

NCT05309304 ↗

Phase 1 Completed 24 enrolled Baxter Healthcare Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Study is to characterize the safety and tolerability of cefazolin after a single IV administration in healthy subjects in a 3 g/150 mL presentation to meet the increasing clinical need for the indication of perioperative prophylaxis in this patient population weighing greater than or equal to (≥) 120 kg.

Timeline

Start
2022-02-14
Primary completion
2022-08-30
Completion
2022-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefazolin Small molecule 2 g Intravenous
Subject Cefazolin Small molecule 3 g Intravenous

Indications

No indication recorded.